Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech

By Ryan McBride Baxter International ($BAX) is grabbing a hemophilia A candidate in late-stage development from partners whose collaboration ran aground last year. A long-time player ...

UPDATED: Biogen bolsters key biz with PhIII win for longer-lasting MS drug

By Ryan McBride Biogen Idec ($BIIB) scored a victory for its bread-and-butter franchise this morning. The large biotech reported that its candidate peginterferon beta-1a, a long-lasting ...

Merck CEO pledges to persist with ‘good’ cholesterol drug program

By Ryan McBride Even as failures in the field pile up, Merck ($MRK) CEO Kenneth Frazier is pushing ahead with a massive development program for a drug to boost HDL or “good” ...

Should Gilead’s quad pill get an exclusivity extension from FDA?

By Tracy Staton One of Gilead Sciences’ ($GILD) 2012 victories was winning FDA approval for its so-called “Quad” pill for AIDS. Officially dubbed Stribild, the drug ...

Amgen tops forecasts for Q4, thanks to new drugs and higher prices

By Tracy Staton Amgen ($AMGN) profits beat analyst expectations. And its sales grew by 11% in the fourth quarter. That’s a feat, considering some of its biggest products–the ...

New BMS drugs will fill yawning Plavix gap, CEO says

97% drop in blood thinner’s Q4 sales partly offset by cancer-drug growth By Tracy Staton Bristol-Myers Squibb’s ($BMY) fourth-quarter sales are about as pure an example ...

FDA won’t appeal free-speech ruling on off-label marketing

By Tracy Staton  Since a federal appellate court called one pharma rep’s off-label marketing a form of protected speech, legal experts have been sifting for clues. How might ...

This Is the Most Exciting IPO of the Year

By Sean Williams To be frank, I very rarely get excited about initial public offerings, or IPOs. Most IPOs tend to be overpriced, and they’re usually surrounded by emotional ...

UPDATE 4-Bristol profit tops forecast; outlook is scaled back

* Profit, excluding items, 47 cts/shr vs Street view 43 cts * Sales $4.19 bln vs Street view $4.12 bln * 2013 forecast is cut, but is in line with Street view * Shares rise 2.5 pct By ...

AstraZeneca: Results Preview

By G. A. Chester LONDON — Blue-chip pharma group AstraZeneca  (LSE: AZN  ) (NYSE:AZN  ) is due to announce its annual results on Jan. 31. At the time of writing, the shares ...

1 Undervalued Generic Producer and 1 Peer Stock With Momentum

By David Gould If the speculation involved with drug development and biotech is not for you, that’s no reason to bail out on the healthcare sector as a whole. Generic producers ...

The Market Waits For NovaBay

By Richard Richter Earlier this week, highly speculative microcap biotech company NovaBay Pharmaceuticals Inc, (NBY) launched a new, investor-oriented mobile app in order “to ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS